EMMPRIN is an independent negative prognostic factor for patients with astrocytic glioma
1Department of Anesthesiology, Xijing Hospital, Fourth Military Medical University, Xi'an, Shaanxi, China.
Abstract:
Extracellular matrix metalloproteinase inducer (EMMPRIN), also known as CD147, is a member of the immunoglobulin superfamily that is present on the surface of tumor cells and stimulates adjacent fibroblasts to produce matrix metalloproteinases (MMPs). It has been proved to be associated with tumor invasion and metastasis in various human malignancies. In our study, the protein expression level of EMMPRIN in 306 cases of astrocytic glioma is investigated by immunohistochemistry assay. Statistical analysis was utilized to evaluate the association of EMMPRIN with clinicopathological characteristics and prognosis of patients. It was proved that EMMPRIN protein expression was increased in glioma compared with that in normal brain tissue. Moreover, EMMPRIN immunohistochemical staining was correlated with WHO grade and Karnofsky performance score for strong positive EMMPRIN staining is more frequently detected in glioma of advanced grade or low KPS score. It is also demonstrated that EMMPRIN could be an independent negative prognostic factor in glioma for patients with glioma of strong EMMPRIN staining tend to have high risk of death. These results proved that EMMPRIN is associated with prognosis of glioma, which may also suggest the potential role of EMMPRIN in glioma management.
Insights
Extracellular matrix metalloproteinase inducer (EMMPRIN), or CD147, is elevated in astrocytic glioma and linked to poorer patient prognosis. Higher EMMPRIN levels correlate with advanced tumor grade and reduced survival, suggesting its role in glioma progression.
Area of Science:
- Neuro-oncology
- Cancer Biology
- Immunology
Background:
- Extracellular matrix metalloproteinase inducer (EMMPRIN), also known as CD147, is implicated in tumor invasion and metastasis.
- EMMPRIN is an immunoglobulin superfamily member found on tumor cells, inducing matrix metalloproteinase (MMP) production by fibroblasts.
Purpose of the Study:
- To investigate the protein expression level of EMMPRIN in astrocytic glioma.
- To evaluate the association of EMMPRIN with clinicopathological characteristics and patient prognosis.
Main Methods:
- Immunohistochemistry assay was used to examine EMMPRIN protein expression in 306 astrocytic glioma cases.
- Statistical analysis was performed to correlate EMMPRIN levels with clinical data.
Main Results:
- EMMPRIN protein expression was significantly increased in glioma tissues compared to normal brain tissue.
- Strong positive EMMPRIN staining correlated with higher WHO grade and lower Karnofsky performance score (KPS).
- EMMPRIN was identified as an independent negative prognostic factor, with strong staining associated with increased mortality risk.
Conclusions:
- EMMPRIN expression is associated with advanced astrocytic glioma.
- EMMPRIN levels correlate with poor prognosis and may serve as a potential therapeutic target in glioma management.
